Annexon Biosciences CEO Doug Love considers Guillain-Barré syndrome — also known as GBS — to be the “most unique disease” he’s worked on in 25 years in biotech because of its sudden onset. A rare ...

Almost 900 comments have been submitted as of Monday afternoon. GBS is the company that developed the ZoneCasting geotargeting technology, which we have covered extensively here and that recently was ...

In 2024, 42% of GBS organizations piloted Gen AI, and 63% of these early adopters reported measurable gains in productivity, cost savings, and service quality. With AI’s transformational ...